September 16, 2024 8:16am
While Friday’s aftermarket show bouts of volatility as Fed interest rate decision looms after the Nasdaq led markets higher to nab its best week of the year + 6%.
News: Voyager Therapeutics (VYGR +$0.38) the joint steering committee with its collaborator Neurocrine Biosciences (NBIX +$0.97) has selected a development candidate in a gene therapy program for the potential treatment of an undisclosed neurological disease. The candidate leverages an intravenously administered, blood-brain barrier-penetrant, novel capsid derived from Voyager’s TRACER™ capsid discovery platform. Selection of the development candidate triggered a $3 million milestone payment to Voyager to receive in the fourth quarter of 2024.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Never leave an investor uninformed
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Monday: The pre-open Dow futures are UP +0.25% or (+108 points), the S&P futures are DOWN -0.02% or (-1 points) and the Nasdaq futures are DOWN -0.31% or (-61 points)
- Stock futures were mixed and subject to further change Monday,
- European markets mixed,
- Asia-Pacific markets rose.
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …
Friday: The Dow closed UP +297.01 points or +0.72%, the S&P closed UP +30.26 points or +0.54% while the Nasdaq closed UP +114.30 points or +0.65%
- Thursday’s advance/decline line ended with a negative close at the close of 16 incliner, 17 decliners and 2 flats
Economic Data Docket: the Fed announce their will bring down interest rates?
Friday’s RegMed Investors (RMi) Closing bell: “cell and gene therapy sector sentiment rockets as volatility roared, investors or trading programs?” … https://www.regmedinvestors.com/articles/13616
Q3/24:
- September – 4 positive and 4 negative close
- August – I neutral, 10 positive and 11 negative closes
- July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.
A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Yet again, I am passing on forecasting the daily indications as Friday’s expectation in the aftermarket fluctuated while the pre-open waits for the all-clear alarm … it is still a mix of ups, downs and just unknowns.
The BOTTOM LINE: I am STILL wondering if … sentiment is moribund.
Keep overall exposure low and be ready to exit quickly.
As I have joked, “uncle algo and his electronic trading dwarfs” come to roost” until they fly away!
Moving forward, I believe the cell and gene therapy sector equities could be a bit rocky.
Traders and investors are nervous about the coming week’s economic releases …
Stocks are set to begin reversing Monday's sharp rebound, which saw the major gauges surge over 1% as investors went post-rout bargain hunting.
- Volatility is stalking the markets as investors waver between hopes for a hefty 0.5% rate cut from the Federal Reserve and worries about risks of recession.
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
